Æterna Zentaris Inc.

Details Æterna Zentaris Inc. Æterna Zentaris Inc.

www.aezsinc.com

Quebec

Quebec City

Québec

Corporation

active

Æterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy. Our pipeline encompasses compounds at all stages of development, from drug discovery through marketed products. The highest priorities in oncology are our Phase 3 program with perifosine in multiple myeloma and our Phase 2 program in multiple cancers, including metastatic colon cancer, as well as our Phase 2 program with AEZS 108 in advanced endometrial and advanced ovarian cancer combined with potential developments in other cancer indications. In endocrinology, our lead program is the reactivation of a Phase 3 trial with AEZS 130 (SolorelTM) as a growth hormone (€œGH€?) stimulation test for the diagnosis of GH deficiency in adults (€œAGHD€?).
Country of Ownership: Canada
Year Established: 1991
Exporting: Yes
Primary Industry (NAICS): 541710 - Research and Development in the Physical, Engineering and Life Sciences
Primary Business Activity: Manufacturer / Processor / Producer
Total Sales ($CDN): $50,000,000 +
Number of Employees: 100

Products:
Perifosine - colorectal cancer, kidney cancer and other types of cancer, Perifosine - multiple myeloma, Aezs-108 - ovarian and endometrial cancer, Aezs-130 - therapeutic treatment for growth hormone deficiencies, Solorel tm (aezs-130) - diagnostic test for growth hormone deficiencies, Aezs-120 - prostate cancer and melanoma, Aezs-112 - solid tumors

Affiliated with

Also associated with

No associations

Rating

Æterna Zentaris Inc. does not yet have a rating. At this time, there are no reviews or comments for this company.

If you have personal experience with Æterna Zentaris Inc., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Æterna Zentaris Inc. will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-COD-O-2623